Phillips Jessica, Chen Jenny H C, Ooi Esther, Prunster Janelle, Lim Wai H
Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.
School of Medicine, University of Wollongong, Wollongong, NSW, Australia.
Front Clin Diabetes Healthc. 2021 Aug 23;2:731574. doi: 10.3389/fcdhc.2021.731574. eCollection 2021.
The burden of type 2 diabetes and related complications has steadily increased over the last few decades and is one of the foremost global public health threats in the 21st century. Diabetes is one of the leading causes of chronic kidney disease and kidney failure and is an important contributor to the cardiovascular morbidity and mortality in this population. In addition, up to one in three patients who have received kidney transplants develop post-transplant diabetes, but the management of this common complication continues to pose a significant challenge for clinicians. In this review, we will describe the global prevalence and temporal trend of kidney failure attributed to diabetes mellitus in both developing and developed countries. We will examine the survival differences between treated kidney failure patients with and without type 2 diabetes, focusing on the survival differences in those on maintenance dialysis or have received kidney transplants. With the increased availability of novel hypoglycemic agents, we will address the potential impacts of these novel agents in patients with diabetes and kidney failure and in those who have developed post-transplant diabetes.
在过去几十年中，2型糖尿病及其相关并发症的负担一直在稳步增加，是21世纪全球最主要的公共卫生威胁之一。糖尿病是慢性肾脏病和肾衰竭的主要病因之一，也是该人群心血管疾病发病率和死亡率的重要促成因素。此外，接受肾移植的患者中，高达三分之一会发生移植后糖尿病，但这种常见并发症的管理对临床医生来说仍然是一项重大挑战。在这篇综述中，我们将描述发展中国家和发达国家中归因于糖尿病的肾衰竭的全球患病率和时间趋势。我们将研究接受治疗的肾衰竭患者中伴有和不伴有2型糖尿病的生存差异，重点关注维持性透析患者或接受肾移植患者的生存差异。随着新型降糖药物的可及性增加，我们将探讨这些新型药物对糖尿病和肾衰竭患者以及发生移植后糖尿病患者的潜在影响。
